Healthcare technology company HCTG has launched ConsensusAI, a real-time patient consultation tool designed to expedite medical delivery-of-care decisions using the Healthcasts platform.
The tool is powered by artificial intelligence (AI) generated by Healthcasts’ healthcare provider (HCP) member network and analyses several clinical consultations in real time.
It is intended to help improve patient diagnoses and treatment selection by giving healthcare professionals immediate access to major insights.
HCTG president Erik Dalton said: “The compression and acceleration of crowdsourced HCP-provided data is transforming how HCPs are able to deliver superior treatment and improved outcomes for their patients while saving themselves hours of research.
“Our investment into technologies that support HCPs and their practices through Healthcasts will result in a faster and more accurate treatment decision for each individual patient.”
As a physician-member organisation, Healthcasts aims to enable scientific consultation and collaboration among leading healthcare professionals in the US.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataBased in New York, the company has facilitated the exchange of data between HCPs for more than 20 years.
Healthcasts founder and CEO John Theobald said: “60% of HCPs use Healthcasts during office hours and 66% of HCPs have adjusted their treatment plans based on information exchanged through our platform.
“With ConsensusAI, HCPs are further empowered to accelerate the clinical use of their own real-world data, transforming how they help themselves, their peers and their patients at the same time.”
Italian medical laboratory Gruppo Centro Servizi Medici (CSM) recently installed SOPHiA DDM, a platform that uses AI and patented technologies to examine and interpret next-generation sequencing data.
Developed by Sophia Genetics, the platform is used by hospitals, laboratories and biopharmaceutical institutions worldwide to analyse complex multimodal data sets and different diagnostic modalities.
CSM intends to use the platform to improve the detection and categorisation of hereditary cancers, as well as help clinical researchers identify genomic profiles that respond effectively to specific therapies.